Moderna released data from a Phase 2-3 clinical trial showing its bivalent COVID-19 booster shot performed better against the BA.4 and BA.5 omicron subvariants.
Moderna released data from a Phase 2-3 clinical trial showing its bivalent COVID-19 booster shot performed better against the BA.4 and BA.5 omicron subvariants.